Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

World Bank Report Predicts Contracting Global Economy Will Hurt Poorest Countries
The World Bank released a report Monday, projecting "a 2.9 percent contraction in global GDP this year, as rich countries contract by 4.5 percent," the Wall Street Journal reports. "The crisis of the past two years is having dramatic effects on capital flows to developing countries, and the world appears to be entering an era of lower growth," World Bank Chief Economist Justin Lin said (Burns, Wall Street Journal, 6/22).
generic viagra online
San Francisco Chronicle Profiles U.S. Global AIDS Coordinator
"Dr. Eric Goosby wasted no time starting his new job as the U.S. global AIDS coordinator. He flew from the Bay Area to Geneva hours after his confirmation by the Senate and was sworn in when he landed ò€¦ The ambassador is approaching his post with the urgency of a clinician who has spent more than 25 years fighting the disease," the San Francisco Chronicle writes.
News of the day
Eleven Accussed Of Scamming Medicare In Michigan
Eleven people were charged in an indictment unsealed on Thursday with "scamming Medicare to get painkillers," the Associated Press reports. "A federal indictment in Detroit says the government unwittingly paid more than $480,000 to a phony health-care business that was a front for acquiring and selling painkillers." Authorities say Quick Response Medical Professionals paid people up to $220 to be seen by a doctor and that those visits were then reimbursed by Medicare. The case also involves thousands of doses of OxyContin worth more than $5 million that were sold during 2007 and 2008. The AP noted that "the government says Medicare and Medicaid fraud costs taxpayers billions each year" (6/4).
Nutrition

Baxter Advances To Full-Scale Production Of A/H1N1 Vaccine

Baxter International Inc. (NYSE: BAX) announced that it has completed testing and evaluation of the A/H1N1 influenza virus and is now in full-scale production of a commercial A/H1N1 vaccine using its Vero cell culture technology. Baxter received an A/H1N1 strain from the U.S. Centers for Disease Control and Prevention [a World Health Organization (WHO) Collaborating Center] in early May and is diligently working to deliver a pandemic vaccine for use as early as July. WHO raised the pandemic alert level to phase 6, indicating a global influenza pandemic involving the 2009 A/H1N1 strain. Baxter is in contact with WHO and other global public health authorities regarding the pandemic. A number of national public health authorities have existing pandemic agreements with Baxter that allow them to place orders for a vaccine now that a pandemic has been declared by WHO. These public health authorities will be evaluating their needs to determine their orders for vaccine supply. Despite the company"s existing obligations to supply vaccine under a pandemic phase 6 alert, Baxter is also committed to working with WHO to allocate a portion of the company"s commercial production to address global public health issues deemed most urgent. Using its Vero cell technology, Baxter has received European Medicines Agency (EMEA) approval for a mock-up pandemic vaccine called CELVAPAN, the brand name for the company"s pandemic vaccine. The qualification, development and manufacturing processes used in gaining mock-up licensure for CELVAPAN apply as the company uses this new influenza A/H1N1 virus strain to produce a pandemic vaccine. The CELVAPAN EMEA licensure supports fast track approval of a pandemic vaccine containing the A/H1N1 virus strain. Baxter will submit the A/H1N1 vaccine for approval upon completion of initial manufacturing runs. Baxter"s research and development, manufacturing capabilities and pandemic planning expertise allow the company to efficiently develop candidate vaccines against potentially emerging influenza viruses. Baxter believes that its Vero cell technology can be used to safely and reliably produce a vaccine in response to this global public health issue. It is possible that Baxter"s Vero cell technology may offer advantages, in that it may allow more rapid production and delivery of pandemic vaccines. Baxter International Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009